Federal Register / Vol. 74, No. 106 / Thursday, June 4, 2009 / Notices 26867 

Injury Prevention and Control (NCIPC), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The health burden of Intimate Partner 

Violence (IPV), Sexual Violence (SV) 

and stalking are substantial. 

Approximately 1.5 million women and 

834,700 men are raped and/or 

physically assaulted by an intimate 

partner each year. Women are more 

likely than men to be victimized by 

almost every type of IPV, including 

rape, physical assault, and stalking by a 

current or former intimate partner. The 

health care costs of IPV exceed $5.8 

billion each year, nearly $3.9 billion of 

which is for direct medical and mental 

health care services. 

SV also has a profound and long-term 

impact on the physical and mental 

health of the victim. Existing estimates 

of lifetime experiences of rape range 

from 15% to 36% for females. Sexual 

violence against men, although less 

prevalent, is also a public health 

problem; approximately, 1 in 6 women 

and 1 in 33 men have experienced an 

attempted or completed rape in their 

lifetime. Over 302,000 women and 

92,000 men were raped in the past 12 

months. Thirty percent of rape victims 

experience major depressions at some 

time in their lives; 33% of victimized 

women and 24.2% of victimized men 

are counseled by a health professional; 

31% develop post traumatic stress 

disorder; 33% contemplate suicide; and 

13% attempt suicide. 

Each year, approximately 1 million 

women and 371,000 men in the United 

States are stalked. There is a strong link 

between stalking and other forms of 

violence in intimate relationships; 81% 

of women who were stalked by a current 

or former intimate partner were also 

physically assaulted by that partner and 

31% were sexually assaulted by that 

partner. Furthermore, 76% of female 

victims of intimate partner homicides 

were stalked by their partners before 

they were killed. 

Currently, the United States lacks a 

national data source that systematically 

and routinely collects valid and reliable 

information on the magnitude and 

trends in IPV, SV and stalking. Such a 

system is needed to (1) help formulate 

public policies and prevention strategies 

related to IPV, SV and stalking; (2) guide 

and evaluate progress in reducing the 

huge health and social burden 

associated with IPV, SV and stalking; 

and (3) improve the effectiveness of 

federal agencies responding to IPV, SV 

and stalking. 

In order to address this important 

public health problem, CDC plans to 

develop a national surveillance system 

that will generate national and state 

level estimates of IPV, SV and stalking. 

A total of 73,318 eligible households 

will be screened; out of the households 

screened approximately 38,318 will not 

consent or agree to participate and 

35,000 will complete the survey each 

year. The survey will be conducted 

among English and/or Spanish speaking 

male and female adults (18 years and 

older) living in the United States. 

There are no costs to respondents 

other than their time. The total 

estimated annual burden hours are 

18,249. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

responses 

Number of responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Households ..................................................... Screened ........................................................ 73,318 1 3/60 

Surveyed ........................................................ 35,000 1 25/60 

Dated: May 28, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–13044 Filed 6–3–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0246] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Establishing and 

Maintaining a List of U.S. Dairy 

Product Manufacturers/Processors 

With Interest in Exporting to Chile 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension of an existing collection of 

information, and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

the information collection provisions of 

the guidance document entitled 

‘‘Establishing and Maintaining a List of 

U.S. Dairy Product Manufacturers/ 

Processors With Interest in Exporting to 

Chile.’’ 

DATES: Submit written or electronic 

comments on the collection of 

information by August 3, 2009. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to http:// 

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Information 

Management (HFA–710), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–796–3794. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

26868 Federal Register / Vol. 74, No. 106 / Thursday, June 4, 2009 / Notices 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Establishing and Maintaining a List of 

U.S. Dairy Product Manufacturers/ 

Processors With Interest in Exporting to 

Chile (OMB Control Number 0910– 

0509)—Extension 

As a direct result of discussions that 

have been adjunct to the U.S./Chile Free 

Trade Agreement, Chile has recognized 

FDA as the competent U.S. food safety 

authority and has accepted the U.S. 

regulatory system for dairy inspections. 

Chile has concluded that it will not 

require individual inspections of U.S. 

firms by Chile as a prerequisite for 

trade, but will accept firms identified by 

FDA as eligible to export to Chile. 

Therefore, in the Federal Register of 

June 22, 2005 (70 FR 36190), FDA 

announced the availability of a revised 

guidance document entitled 

‘‘Establishing and Maintaining a List of 

U.S. Dairy Product Manufacturers/ 

Processors With Interest in Exporting to 

Chile.’’ The guidance can be found at 

http://www.cfsan.fda.gov/ 

guidance.html. The guidance document 

explains that FDA has established a list 

that is provided to the Government of 

Chile and posted on http:// 

www.cfsan.fda.gov/~comm/ 

expcllst.html, which identifies U.S. 

dairy product manufacturers/processors 

that have expressed interest to FDA in 

exporting dairy products to Chile, are 

subject to FDA jurisdiction, and are not 

the subject of a pending judicial 

enforcement action (i.e., an injunction 

or seizure) or a pending warning letter. 

The term ‘‘dairy products,’’ for purposes 

of this list, is not intended to cover the 

raw agricultural commodity raw milk. 

Application for inclusion on the list is 

voluntary. However, Chile has advised 

that dairy products from firms not on 

this list could be delayed or prevented 

by Chilean authorities from entering 

commerce in Chile. The guidance 

explains what information firms should 

submit to FDA in order to be considered 

for inclusion on the list and what 

criteria FDA intends to use to determine 

eligibility for placement on the list. The 

document also explains how FDA 

intends to update the list and how FDA 

intends to communicate any new 

information to Chile. Finally, the 

guidance notes that FDA considers the 

information on this list, which is 

provided voluntarily with the 

understanding that it will be posted on 

FDA’s Web site and communicated to, 

and possibly further disseminated by, 

Chile, to be information that is not 

protected from disclosure under 5 

U.S.C. 552(b)(4). Under the guidance, 

FDA recommends that U.S. firms that 

want to be placed on the list send the 

following information to FDA: (1) Name 

and address of the firm and the 

manufacturing plant; (2) name, 

telephone number, and e-mail address 

(if available) of the contact person; (3) 

a list of products presently shipped and 

expected to be shipped in the next 3 

years; (4) identities of agencies that 

inspect the plant and the date of last 

inspection; (5) plant number and copy 

of last inspection notice; and, (6) if other 

than an FDA inspection, a copy of last 

inspection report. FDA requests that this 

information be updated every 2 years. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1

Activity No. of 

Respondents 

Annual Frequency 

per Response 

Total Annual 

Responses 

Hours per 

Response Total Hours 

New written requests to be 

placed on the list 15 1 15 1.5 23 

Biannual update 88 1 88 1.0 88 

Occasional updates 25 1 25 0.5 13 

Total 124 

1There are no capital or operating and maintenance costs associated with this collection of information. 

The estimate of the number of firms 

that will submit new written requests to 

be placed on the list, biannual updates 

and occasional updates is based on the 

FDA’s experience maintaining the list 

over the past 4 years. The estimate of 

the number of hours that it will take a 

firm to gather the information needed to 

be placed on the list or update its 

information is based on FDA’s 

experience with firms submitting 

similar requests. FDA believes that the 

information to be submitted will be 

readily available to the firms. 

To date, over 175 producers have 

sought to be included on the list. FDA 

estimates that, each year, approximately 

15 new firms will apply to be added to 

the list. We estimate that a firm will 

require 1.5 hours to read the guidance, 

to gather the information needed, and to 

prepare a communication to FDA that 

contains the information and requests 

that the firm be placed on the list for a 

total of 22.5 hours, rounded to 23. 

Under the guidance, every 2 years each 

producer on the list must provide 

updated information in order to remain 

on the list. FDA estimates that each year 

approximately half of the firms on the 

list, 88 firms (175 × 0.5 = 87.5, rounded 

to 88), will resubmit the information to 

remain on the list. We estimate that a 

firm already on the list will require 1.0 

hours to biannually update and 

resubmit the information to FDA, 

including time reviewing the 

information and corresponding with 

FDA, for a total of 88 hours. In addition, 

FDA expects that, each year, 

approximately 25 firms will need to 

submit an occasional update and each 

firm will require 0.5 hours to prepare a 

communication to FDA reporting the 

change, for a total of 12.5 hours, 

rounded to 13. 

Federal Register / Vol. 74, No. 106 / Thursday, June 4, 2009 / Notices 26869 

Dated: May 28, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–13041 Filed 6–3–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: 

Title: Emergency Contingency Fund 

for Temporary Assistance for Needy 

Families (TANF) Programs. 

OMB No.: New Collection. 

Description: On February 17, 2009, 

the President signed the American 

Recovery and Reinvestment Act of 2009 

(Recovery Act), which establishes the 

Emergency Contingency Fund for State 

TANF Programs (Emergency Fund) as 

section 403(c) of the Social Security Act 

(the Act). This legislation provides up to 

$5 billion to help States, Territories, and 

Tribes in fiscal year (FY) 2009 and FY 

2010 that have an increase in assistance 

caseloads and basic assistance 

expenditures, or in expenditures related 

to short-term benefits or subsidized 

employment. The Recovery Act made 

additional changes to TANF—extending 

supplemental grants through FY 2010, 

expanding flexibility in the use of TANF 

funds carried over from one fiscal year 

to the next, and adding a hold-harmless 

provision to the caseload reduction 

credit for States and Territories serving 

more TANF families. 

The Emergency Fund is intended to 

build upon and renew the principles of 

work and responsibility that underlie 

successful welfare reform initiatives. 

The Emergency Fund provides 

resources to States, Territories, and 

Tribes to support work and families 

during this difficult economic period. 

We plan to issue a Program 

Instruction accompanied by the 

Emergency Fund Request Form (OFA– 

100), and instructions for jurisdictions 

to complete the OFA–100 to apply for 

emergency funds. 

Failure to collect this data would 

compromise ACF’s ability to monitor 

caseload and expenditure data that must 

increase in order for jurisdictions to 

receive awards under the Emergency 

Fund. 

Documentation maintenance on 

financial reporting for the Emergency 

Fund is governed by 45 CFR 92.20 and 

45 CFR 92.42. 

Respondents: State, Territory, and 

Tribal agencies administering the 

Temporary Assistance for Needy 

Families (TANF) Program that are 

applying for the Emergency Fund. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses 

per respondent 

Average 

burden hours 

per response 

Total 

burden hours 

TANF Emergency Fund Request Form, OFA–100 ....................................... 93 5 24 11,160 

Estimated Total Annual Burden 

Hours: 11,160. 

In compliance with the requirements 

of Section 506(c)(2)(A) of the Paperwork 

Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: June 1, 2009. 

Janean Chambers, 

Reports Clearance Officer. 

[FR Doc. E9–13017 Filed 6–3–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences, Special Emphasis 

Panel; Minority Biomedical Research 

Support. 

Date: June 25–26, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency-Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: John J. Laffan, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, Room 3AN18J, Bethesda, 

MD 20892, 301–594–2773, 

laffanjo@mail.nih.gov. 

Name of Committee: National Institute of 

General Medical Sciences, Special Emphasis 

Panel; ARRA Wound Healing Grant 

Applications. 

Date: July 1, 2009. 

Time: 3 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, Room 3AN12, 45 Center 

Drive, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Meredith D. TempleO’Connor, PhD, Scientific Review Officer, 

Office of Scientific Review, National Institute 

of General Medical Sciences, National